Global Drug Delivery Markets Up $3.6B in 2020 Driven by Coronavirus

Posted by Life Science Intelligence on Apr 17, 2020 5:13:36 PM
Find me on:

Drug delivery products encompass injection devices, infusion pumps and related administration sets, gravity administration sets, vascular access devices, enteral therapy pumps and sets, and external insulin pumps and sets. Our definition specifically excludes orally administered agents, depot and transdermal drugs, and implantable pain pumps.

Drug delivery is ubiquitous within health care delivery, employed across the full array of health delivery vehicles. It is especially important for hospitalized patients, who require the administration of fluids and drugs to prevent dehydration, treat various conditions, and provide an open route for emergency treatment. As such, it is one of the technology segments benefitting from the current COVID-19 pandemic.

COVID-19 ImpactTracker

Drug delivery products expected to see the greatest increase in demand due to the Coronavirus pandemic include infusion pumps and proprietary sets (essential on both hospital floors and especially in intensive care wards treating the most serious COVID-19 patients), vascular access devices, and gravity administration sets. Syringes are also important to deliver medications, including insulin to hospitalized diabetic patients who are at heightened risk for the COVID-19 virus. We have assumed demand for enteral therapy devices and insulin pumps and sets will be minimally impacted by the pandemic, if even that, and so have forecast them to experience “normal” real annual growth rates through 2024.

Combined sales of pumps and sets are projected to increase nearly 47% in 2020 to $7.1 billion, a 42% increase over the normal expected level.  (In addition to standard treat-ment of hospitalized patients COVID-19 patients, we believe the pumps will be required to deliver the promising treatments being used and developed to prevent COVID-19 deaths.)  Because the $7.1 billion sales include numerous new pumps in addition to the sets that typically contribute the largest share of the market, we are forecasting sales to gradually decline through 2022 as the pandemic’s effects subside, approaching normal levels in 2023 and 2024.

For more details visit:

Stay connected with our latest posts:

About the Author

Life Science Intelligence (LSI) helps medtech executives make better strategic decisions by delivering unique market data and business insights. For over 13 years LSI has been working with industry giants – Johnson & Johnson, Medtronic, Abbott, Stryker, Cardinal, Boston Scientific, and Becton Dickinson, among others. LSI products are also leveraged by the most successful start-ups, innovators, investors, and service companies that compete in medtech. LSI is the organizer of The Emerging Medtech Summit held annually in Southern California.

Contact LSI here, via phone 714 847 3540, or email